|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
This is a double-blinded, two-arm, randomized, placebo controlled study comparing the virological efficacy of add-on sirolimus with standard care to placebo and standard care. Virological efficacy is defined as the change from baseline to day 7 in SARS-CoV-2 viral burden measured by quantitative real-time polymerase chain reaction.
Description: SARS-CoV-2 viral burden will be quantified for both arms using a qRT-PCRMeasure: Change in SARS-CoV-2 viral burden from baseline to day 7 of treatment Time: Baseline, and days 1, 2, 3, 4, 5, 6, & 7 post-dose for all patients
Description: SARS-CoV-2 viral burden will be quantified for both arms using a qRT-PCRMeasure: Change in SARS-CoV-2 viral burden at days 1-6 Time: Days 1, 2, 3, 4, 5, and 6 post-dose for all patients
Description: Safety and tolerability of sirolimus in patients with COVID-19Measure: Rate of treatment emergent adverse events Time: Days 1, 2, 3, 4, 5, and 6 post-dose for all patients
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports